You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

 

Online download statistics by month:

Online download statistics by month: May 2022 to March 2024

AbstractFullPdf
May 2022388398147
Jun 202218118843
Jul 202218218246
Aug 202215315331
Sep 202217217446
Oct 202214715248
Nov 2022878734
Dec 2022858529
Jan 2023646519
Feb 2023767852
Mar 2023616238
Apr 2023505032
May 2023454634
Jun 2023464616
Jul 2023434330
Aug 2023444419
Sep 2023333317
Oct 2023303019
Nov 2023393920
Dec 2023686936
Jan 2024525228
Feb 2024545421
Mar 2024585945
Total21582189850